According to a recent LinkedIn post from Cognition, health tech firm Evinova within the AstraZeneca group is using Cognition’s AI software engineer Devin across multiple software development workflows. The post indicates Devin is being applied to regulatory documentation, bug triage, tech stack migrations, and test automation, with a strong emphasis on end-to-end task ownership and regulatory auditability.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights a reported productivity gain in producing GxP regulatory documentation, suggesting Devin enables first drafts around eight times faster than traditional processes that took 35–40 hours across teams. With first drafts characterized as roughly 90% accurate, engineers are portrayed as shifting their time toward review rather than initial creation, which could lower development cycle times and improve cost efficiency.
A quoted comment from Evinova’s CTO frames this AI adoption as central to how the company designs and runs modern clinical trials, positioning AI-native software development as a prerequisite for credibly transforming customer workflows. For Cognition, this use case implies growing traction of Devin in highly regulated life sciences environments, which may support pricing power, stickier enterprise relationships, and differentiation versus generic AI coding tools.
If such productivity and compliance-oriented benefits generalize beyond Evinova, Cognition could see expanded demand from other pharmaceutical and clinical research organizations seeking to accelerate trial-related software while maintaining regulatory standards. For investors, the post points to potential for Devin to tap into large, compliance-heavy software budgets, though the claims remain anecdotal and do not provide details on contract size, recurring revenue, or overall customer penetration.